Literature DB >> 26049088

Physical Activity Measurement Accuracy in Individuals With Chronic Lung Disease: A Systematic Review With Meta-Analysis of Method Comparison Studies.

Satvir S Dhillon1, Carmen A Sima1, Ashley R Kirkham2, Nafeez Syed1, Pat G Camp3.   

Abstract

OBJECTIVE: To investigate the accuracy of physical activity measurement strategies in adults with chronic lung disease. DATA SOURCES: MEDLINE, Embase, and CINAHL databases were searched from inception to September 30, 2014. STUDY SELECTION: Studies reporting validity data for devices measuring energy expenditure in comparison with indirect calorimetry or doubly labeled water measurements in chronic lung disease were included. Nine publications in chronic obstructive pulmonary disease (COPD) or cystic fibrosis (CF) from 2294 studies were identified. DATA EXTRACTION: Two reviewers evaluated studies for quality using a modified version of the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) checklist and extracted data relating to population, setting, devices, activity protocols, and energy expenditure. Disagreements were resolved by consensus. DATA SYNTHESIS: Studies were of high quality, with 8 studies scoring at least 9 out of 11 on the QUADAS checklist. In laboratory-based settings, the SenseWear multisensor accurately estimated energy expenditure during walking compared with indirect calorimetry (pooled mean difference, -0.7 kcal/min; 95% confidence interval [CI], -2.5 to 1.1) in COPD, but overestimated it in CF. However, 2 studies in COPD and CF showed the SenseWear multisensor accurately estimated energy expenditure during lifestyle tasks compared with indirect calorimetry (pooled mean difference, .18 kcal/min; 95% CI, -.13 to .49). The Digi-Walker pedometer underestimated energy expenditure compared with indirect calorimetry in COPD (mean difference walking, -2.4 kcal/min; 95% CI -3.4 to -1.1; mean difference lifestyle tasks, -2.3 kcal/min; 95% CI, -2.8 to -1.8). In free-living settings, the ActiReg multisensor accurately measured energy expenditure in COPD (mean difference, -21 kcal/d; 95% CI, -133.9 to 91.9), whereas the Flex Heart Rate Method underestimated energy expenditure in CF (mean difference, -454.1 kcal/d; 95% CI, -727 to -181.2).
CONCLUSIONS: Energy expenditure estimation was accurate from the SenseWear and ActiReg multisensors during laboratory-based and free-living testing. Future studies warrant investigation of activity measures in other lung diseases and in specific ranges of lung disease severity.
Copyright © 2015 American Congress of Rehabilitation Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cystic fibrosis; Exercise; Physical exertion; Pulmonary disease, chronic obstructive; Rehabilitation; Validation studies as topic

Mesh:

Year:  2015        PMID: 26049088     DOI: 10.1016/j.apmr.2015.05.015

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  5 in total

1.  Counting Steps: A New Way to Monitor Patients with Pulmonary Arterial Hypertension.

Authors:  Sameep Sehgal; Ananda Chowdhury; Fadi Rabih; Abhishek Gadre; Margaret M Park; Manshi Li; Xiaofeng Wang; Kristin B Highland
Journal:  Lung       Date:  2019-05-29       Impact factor: 2.584

2.  Physical activity in incident patients with pulmonary arterial and chronic thromboembolic hypertension.

Authors:  Stéphanie Saxer; Mona Lichtblau; Charlotte Berlier; Elisabeth D Hasler; Esther I Schwarz; Silvia Ulrich
Journal:  Lung       Date:  2019-07-01       Impact factor: 2.584

Review 3.  Physical Activity Monitoring in Patients with Neurological Disorders: A Review of Novel Body-Worn Devices.

Authors:  Oonagh M Giggins; Ieuan Clay; Lorcan Walsh
Journal:  Digit Biomark       Date:  2017-06-12

4.  Interventions for promoting physical activity in people with chronic obstructive pulmonary disease (COPD).

Authors:  Angela T Burge; Narelle S Cox; Michael J Abramson; Anne E Holland
Journal:  Cochrane Database Syst Rev       Date:  2020-04-16

Review 5.  Clinical Utility of Elosulfase Alfa in the Treatment of Morquio A Syndrome.

Authors:  Chung-Lin Lee; Chih-Kuang Chuang; Huei-Ching Chiu; Ru-Yi Tu; Yun-Ting Lo; Ya-Hui Chang; Shuan-Pei Lin; Hsiang-Yu Lin
Journal:  Drug Des Devel Ther       Date:  2022-01-10       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.